QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021Business Wire • 02/09/21
QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation TestingBusiness Wire • 01/28/21
QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021Business Wire • 01/20/21
QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the CoronavirusBusiness Wire • 01/20/21
QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit FacilityBusiness Wire • 12/17/20
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021Business Wire • 12/11/20
QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell ResponseBusiness Wire • 12/07/20
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and NeckBusiness Wire • 11/18/20
QIAGEN Launches NeuMoDx Multiplex Test to Complete Range of SARS-CoV-2 Testing Solutions in Europe and Other MarketsBusiness Wire • 11/16/20
QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per HourBusiness Wire • 11/11/20